Cobra BioManufacturing Release: Hawaii Biotech, Inc. Finishes Phase I West Nile Clinical Trial

Published: Jan 20, 2009

Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that Hawaii Biotech Inc. has completed the dosing phase of a Phase I clinical trial for a West Nile vaccine using vaccine that Cobra Biomanufacturing produced for Hawaii Biotech.

Hawaii Biotech’s vaccine technology is based on the production of proprietary genetically engineered antigens (proteins) that produce immune responses equivalent to or better than traditional live or inactivated virus approaches. The vaccine also has the potential for a significantly improved safety profile compared to traditional approaches. The West Nile vaccine product consists of a recombinant protein and adjuvant.

CEO Simon Saxby said: “It is gratifying to see Cobra-produced material progressing through human clinical trials. As a contract manufacturer, our success is closely linked to our clients’ success, and it is extremely rewarding when collaborations with our clients achieve the planned goals through the combined teams’ efforts.

We wish Hawaii Biotech every success as they analyze their Phase I data.”

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.

Back to news